T-cell profiles derived from blood and renal biopsy may be novel biomarkers of lupus nephritis treatment response, study findings suggest.

After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...

T cells are crucial components of our immune system, serving as critical protectors against infection and disease. But there ...

CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American ...

Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager (TCE) innovation, today announced the presentation of new preclinical data for ENA101, its first-in-class bispecific T ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

The research is happening at Roswell Park Comprehensive Cancer Center.

The peripheral T-cell lymphoma treatment market is witnessing steady growth, primarily driven by the increasing incidence, leading to an increased patient population, which fuels the ongoing treatment ...